Hwa, Yi L.
Gertz, Morie A.
Kumar, Shaji K. http://orcid.org/0000-0001-5392-9284
Lacy, Martha Q.
Buadi, Francis K.
Dingli, David
Kapoor, Prashant
Zeldenrust, Steve R.
Leung, Nelson http://orcid.org/0000-0002-5651-1411
Hayman, Susanne R.
Gonsalves, Wilson I.
Kourelis, Taxiarchis V.
Warsame, Rahma
Go, Ronald S. http://orcid.org/0000-0002-8284-3495
Muchtar, Eli http://orcid.org/0000-0003-2210-2174
Hobbs, Miriam A.
Fonder, Amie L.
Russell, Stephen
Kyle, Robert A.
Rajkumar, S. Vincent
Dispenzieri, Angela
Article History
Received: 9 October 2018
Revised: 26 December 2018
Accepted: 18 January 2019
First Online: 8 February 2019
Compliance with ethical standards
:
: AD: received research funding from Jannsen, Takeda, Celgene, Pfizer, Alnylam, Prothena, and GSK, and serves on the advisory board of Takeda and Intellia. MAG: received funding from Amgen, Prothena, Annexon, Appellis, Johnson and Johnson, and Celgene consultancy (Milleniu), and honoraria from Celgene, Millenium, Onyx, Novartis, Smith Kline, Prothena, and Ionis. SK: received research grants for clinical trials from Celgene, Takeda, Janssen, BMS, Sanofi, KITE, Merck, Abbvie, Medimmune, Novartis, Roche-Genentech, and Amgen. DD: received research funding from Karyopharm Therapeutics, Amgen, and Millenium Pharmaceuticals. NL: serves on the advisory board of Takeda and Prothena. PK: receives funding from Takeda, Sanofi, and Amgen. MQL: received research funding from Celgene. The remaining authors declare no conflict of interest.